HONG KONG – A novel class of antitubercular drugs, the indol carboxamides, has been shown safe and effective against clinical Mycobacterium tuberculosis isolates in preclinical studies, report Novartis Institute for Tropical Diseases (NITD) in Singapore researchers in the latest issue of Science Translational Medicine.